Impaired Humoral Response to Third Dose of BNT162b2 mRNA COVID-19 Vaccine Despite Detectable Spike Protein-specific T cells in Lung Transplant Recipients
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064203%3A_____%2F22%3A10434736" target="_blank" >RIV/00064203:_____/22:10434736 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11110/22:10434736 RIV/00216208:11130/22:10434736
Result on the web
<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=ycpm8mV93k" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=ycpm8mV93k</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1097/TP.0000000000004021" target="_blank" >10.1097/TP.0000000000004021</a>
Alternative languages
Result language
angličtina
Original language name
Impaired Humoral Response to Third Dose of BNT162b2 mRNA COVID-19 Vaccine Despite Detectable Spike Protein-specific T cells in Lung Transplant Recipients
Original language description
The immunogenicity of the mRNA coronavirus disease 2019 vaccine in thoracic organ transplant recipients is poor. Early reports provided evidence of increased immunogenicity after the third mRNA vaccine dose in solid organ transplant recipients. However, the antibody and cellular responses after the third dose of the BNT162b2 vaccine (Pfizer-BioNTech) and its safety in lung transplant recipients (LTRs) are unknown to date. We included 15 LTRs without a history of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection who received 2 doses of the BNT162b2 vaccine 21 d apart with no antibody response. In this cohort, we assessed the antibody and cellular responses immediately before and 3 wk after the third dose administered 3 mo after the second dose. Anti-SARS-CoV-2 immunoglobulin (Ig) G levels were tested by Microblot-Array coronavirus disease 2019 IgG against a mix of recombinant antigens (TestLine Clinical Diagnostics, Brno, Czech Republic). SARS-CoV-2-specific T cells were assessed by detecting intracellular cytokines after a 4-h stimulation of patients' peripheral blood mononuclear cells with 51 overlapping 11mer peptides of the spike receptor-binding domain protein (JPT Peptide Technologies, Berlin, Germany) as we described previously. Závěrem lze říci, že při absenci humorální odpovědi jsme detekovali vznik buněčné odpovědi u 47 % LTR po třetí dávce vakcíny, což by mohlo mít klinický přínos; měřitelná odpověď je však nízká, převážně buněčná a detekovatelná pouze u poloviny pacientů. Spolu s žádnými známkami epizod rejekce by měla být u LTR doporučena třetí dávka, ale s opatrností, že ochrana vakcínou nesmí být větší než částečná.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30213 - Transplantation
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2022
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Transplantation
ISSN
0041-1337
e-ISSN
1534-6080
Volume of the periodical
106
Issue of the periodical within the volume
3
Country of publishing house
US - UNITED STATES
Number of pages
2
Pages from-to
"e183"-"e184"
UT code for WoS article
000759088200003
EID of the result in the Scopus database
2-s2.0-85125157216